GlassScriptPhysician profile
Irene Mamkin
NPI 1326210485
$13,455.81
in general payments reported to CMS, 2019-2025
41 companies · $8,438 in 2025
The $8,438 reported for 2025 was more than what 87% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $845 · 2020: $468 · 2021: $416 · 2022: $795 · 2023: $1,279 · 2024: $1,216 · 2025: $8,438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,225 · Food and Beverage: $4,621 · Travel and Lodging: $1,086.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,225.00 |
| Food and Beverage | $4,621.25 |
| Travel and Lodging | $1,086.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $3,865.22 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $3,255.44 | 2023-2025 | |
| Novo Nordisk INC | $858.90 | 2019-2025 | Sogroya, Wegovy, Norditropin |
| Abbvie INC. | $762.63 | 2019-2025 | |
| Pfizer INC. | $571.53 | 2022-2025 | |
| Insulet Corporation | $471.86 | 2019-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $381.59 | 2019-2025 | Strensiq |
| Dexcom, INC. | $302.03 | 2019-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Biomarin Pharmaceutical INC. | $271.32 | 2023-2025 | |
| Lilly USA, LLC | $259.10 | 2020-2023 | Baqsimi |
| Ascendis Pharma Endocrinology INC | $241.14 | 2022-2025 | Skytrofa |
| Tolmar, INC. | $200.71 | 2023-2025 | Fensolvi |
| Abbott Laboratories | $182.27 | 2020-2024 | Freestyle Libre 3 |
| Tandem Diabetes Care, INC. | $144.74 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $144.26 | 2023-2025 | Crysvita |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $138.41 | 2019-2024 | Supprelin |
| Ipsen Biopharmaceuticals, INC | $137.63 | 2019-2022 | |
| Rhythm Pharmaceuticals, INC. | $137.33 | 2021-2025 | Imcivree, Imcivree |
| Azurity Pharmaceuticals, INC. | $119.41 | 2023-2025 | Triptodur, Triptodur |
| Medtronic, INC. | $117.15 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System |
| Glaxosmithkline, LLC. | $98.86 | 2024-2025 | Nucala |
| Tolmar Pharmaceuticals, INC. | $87.97 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $71.24 | 2020-2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $70.64 | 2019-2023 | Tirosint, Licart |
| Endo USA, INC. | $68.63 | 2024-2025 | Supprelin |
| Arbor Pharmaceuticals, INC. | $59.41 | 2019-2020 | |
| Beta Bionics, INC. | $50.34 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amphastar Pharmaceuticals, INC. | $49.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.63 | 2024-2025 | Eohilia |
| Sandoz INC. | $42.46 | 2019-2022 | |
| Zealand Pharma US, INC. | $41.21 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $40.88 | 2019-2020 | |
| Medtronic Minimed, INC. | $30.50 | 2019-2020 | |
| Travere Therapeutics, INC. | $27.37 | 2022-2023 | Cholbam |
| Sequel Med Tech, LLC | $20.18 | 2025 | Twiist |
| Vertex Pharmaceuticals Incorporated | $17.55 | 2025 | |
| Becton, Dickinson and Company | $15.79 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.03 | 2020 | |
| Amgen INC. | $15.00 | 2019 | |
| Eton Pharmaceuticals, INC. | $13.62 | 2023 | Alkindi |
| Albireo Pharma, INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irene Mamkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.